(NP (NP (NN Expression)) (PP (IN of) (NP (NN 1,25-LRB-OH-RRB-2D3) (NNS receptors))) (PP (IN on) (NP (NP (JJ alveolar) (NNS lymphocytes)) (PP (IN from) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ pulmonary) (JJ granulomatous) (NNS diseases))))))) (. .))
(S (NP-SBJ-41 (NN 1,25-LRB-OH-RRB-2D3)) (VP (VBZ is) (VP (VBN known) (S (NP-SBJ-42 (-NONE- *-41)) (VP (TO to) (VP (VB be) (VP (VBN produced) (NP (-NONE- *-42)) (PP (IN at) (NP (NP (NNS sites)) (PP (IN of) (NP (JJ granulomatous) (NNS reactions))))))))))) (. .))
(S (SBAR-ADV (IN In) (NN order) (TO to) (S (NP-SBJ-44 (-NONE- *-43)) (VP (VB characterize) (NP (NP (DT the) (NN cell) (NNS types)) (SBAR (WHNP-45 (WDT that)) (S (NP-SBJ (-NONE- *T*-45)) (VP (VBP are) (NP-PRD (NP (NNS targets)) (PP (IN for) (NP (DT this) (JJ immunoregulatory) (NN hormone))))))))))) (, ,) (NP-SBJ-43 (PRP we)) (VP (VBP have) (VP (VBN evaluated) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (NN 1,25-LRB-OH-RRB-2D3) (NNS receptors))) (PP (IN on) (NP-COOD (NP (JJ peripheral) (NN blood) (NNS T-lymphocytes)) (CC and) (NP (NP (DT those)) (VP (VBN recovered) (NP (-NONE- *)) (PP (IN from) (NP (DT the) (NN lung))) (PP (IN by) (NP (NP (JJ bronchoalveolar) (NN lavage)) (PP-COOD (PP (IN from) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (JJ pulmonary) (JJ granulomatous) (NNS diseases)) (PRN (-LRB- -LRB-) (NP-COOD (NP (NN tuberculosis)) (CC and) (NP (NN sarcoidosis))) (-RRB- -RRB-)))))) (CC and) (PP (IN from) (NP (JJ normal) (NN control) (NNS subjects)))))) (S (NP-SBJ (-NONE- *)) (VP (VBG using) (NP (JJ combined) (ADJP-COOD (ADJP (JJ autoradiographic)) (CC and) (ADJP (JJ immunohistochemical))) (NNS techniques))))))))))) (. .))
(S (NP-SBJ-COOD (NP (NP (NN Lavage) (NNS T-lymphocytes)) (PP (IN from) (NP (NP (NNS patients)) (PP-COOD (PP (IN with) (NP (NN tuberculosis))) (CC or) (PP (IN with) (NP (NN sarcoidosis))))))) (, ,) (CONJP (CC but) (RB not)) (NP (NP (DT those)) (PP (IN from) (NP (JJ normal) (NN control) (NNS subjects)))) (, ,)) (VP (VBD expressed) (NP (NN 1,25-LRB-OH-RRB-2D3) (NNS receptors)) (SBAR (IN as) (S (NP-SBJ-46 (-NONE- *)) (VP (VBN demonstrated) (NP (-NONE- *-46)) (PP (IN by) (NP-LGS (NP (NP (NN binding)) (PP (IN of) (NP (NN -LCB-3H-RCB-1,25-LRB-OH-RRB-2D3)))) (, ,) (SBAR (WHNP-47 (WDT which)) (S (NP-SBJ-48 (-NONE- *T*-47)) (VP (VBD was) (VP (VBN inhibited) (NP (-NONE- *-48)) (PP-COOD (PP (IN by) (NP-LGS (NP (DT the) (NN presence)) (PP (IN of) (NP (JJ excess) (JJ unlabeled) (NN 1,25-LRB-OH-RRB-2D3))))) (, ,) (CC but) (PP (RB not) (IN by) (NP-LGS (NP (DT the) (NN presence)) (PP (IN of) (NP (JJ unlabeled) (NN 25-LRB-OH-RRB-D3)))))))))))) (PRN (-LRB- -LRB-) (NP (NP (JJ receptor-positive) (NNS lymphocytes)) (: :) (NP-COOD (NP (NP (NN sarcoidosis)) (, ,) (FRAG (NP (QP (CD 20) (CC (- +)) (CD 12)) (NN %)))) (: ;) (NP (NP (NN tuberculosis)) (, ,) (FRAG (NP (QP (CD 31) (CC (- +)) (CD 17)) (NN %)))))) (-RRB- -RRB-)))))) (. .))
(S (PP (IN In) (NP (NN contrast))) (, ,) (NP-SBJ (NP (NN blood) (NNS lymphocytes)) (PP (IN from) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ granulomatous) (NNS diseases)))))) (VP (VBD did) (RB not) (VP (VB express) (NP (JJ detectable) (NN 1,25-LRB-OH-RRB-2D3) (NNS receptors)))) (. .))
(S (NP-SBJ (NP (DT The) (NN percentage)) (PP (IN of) (NP (NP (NN lavage) (NNS T-lymphocytes)) (VP (VBG expressing) (NP (NN 1,25-LRB-OH-RRB-2D3) (NNS receptors)))))) (VP (VBD was) (ADJP-PRD (ADJP (RB significantly) (JJR greater)) (PP (-NONE- *ICH*-105))) (PP (IN for) (NP (NP (NNS patients)) (PP (IN with) (NP (NN tuberculosis))) (VP (VBG presenting) (PP (IN with) (NP (VBN isolated) (JJ hilar) (JJ adenopathy)))))) (PP-105 (IN than) (FRAG (PP (IN for) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ pulmonary) (NP-COOD (NP (NNS infiltrates)) (CC (or and)) (NP (NNS cavities)))))))))) (. .))
(S-COOD (S (NP-SBJ-49 (NN 1,25-LRB-OH-RRB-2D3) (NNS receptors)) (VP (VBD were) (VP (VBN expressed) (NP (-NONE- *-49)) (PP (TO to) (NP (NP (DT a) (JJR greater) (NN extent)) (PP (-NONE- *ICH*-106)))) (PP (IN on) (NP (JJ CD8+) (NNS T-lymphocytes))) (PP-106 (IN than) (FRAG (PP (IN on) (NP (JJ CD4+) (NNS T-lymphocytes))))) (PP (IN in) (NP (NN sarcoidosis)))))) (, ,) (IN whereas) (S (NP-SBJ (NP (NP (NP (DT a) (JJR greater) (NN proportion)) (PP (IN of) (NP (JJ CD4+) (NP (-NONE- *RNR*-50))))) (PP (IN than) (FRAG (PP (IN of) (NP (JJ CD8+) (NP (-NONE- *RNR*-50)))))) (NP-50 (NNS T-lymphocytes))) (PP (IN from) (NP (NP (NNS patients)) (PP (IN with) (NP (NN tuberculosis)))))) (VP (VBD were) (ADJP-PRD (JJ receptor-positive)))) (. .))
(S-COOD (S (NP-SBJ (DT These) (NNS findings)) (VP (VBP support) (NP (DT the) (NN conclusion) (SBAR (IN that) (S (NP-SBJ (NP (DT the) (NN interaction)) (PP (IN of) (NP (NN 1,25-LRB-OH-RRB-2D3))) (PP (IN with) (NP (NP (PRP$ its) (NN receptor)) (PP (IN on) (NP (NNS T-lymphocytes)))))) (VP (MD may) (VP (VB play) (NP (DT an) (JJ important) (NN role)) (PP (IN in) (NP (NP (DT the) (NN regulation)) (PP (IN of) (NP (JJ granulomatous) (NNS reactions)))))))))))) (, ,) (CC but) (S (SBAR-ADV (IN because) (S (NP-SBJ-51 (DT these) (NNS receptors)) (VP (VBP are) (VP (VBN expressed) (NP (-NONE- *-51)) (PP (IN on) (NP (JJ different) (NN lymphocyte) (NNS populations))))))) (, ,) (NP-SBJ (NP (DT the) (JJ net) (NN effect)) (PP (IN of) (NP (DT this) (JJ potent) (JJ immunoregulatory) (NN molecule)))) (VP (VBZ is) (ADJP-PRD (RB likely) (JJ different)) (PP (IN in) (NP-COOD (NP (NN sarcoidosis)) (CC and) (NP (NN tuberculosis)))))) (. .))
